Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Changes in ICD-10 for Sjögren’s Syndrome

From the College  |  October 1, 2020

A code change in the ICD-10 classification for Sjögren’s syndrome was approved by the ICD-10 Coordination and Maintenance Committee in July 2019 and becomes effective October 2020.

Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

Ruth Jessen Hickman, MD  |  October 1, 2020

A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…

RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement

Arthritis & Rheumatology  |  October 1, 2020

The SELECT-EARLY MTX-controlled trial examined the safety and efficacy of upadacitinib, a potent, reversible jakinib, as monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to methotrexate.

Oxford University to Study Adalimumab as Potential COVID-19 Treatment

Josephine Mason & Kate Kelland  |  September 30, 2020

LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown…

FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2020

In August, Abbvie submitted a new drug application for upadacitinib to treat ankylosing spondylitis. And in September, the FDA approved an oral solution of tramadol hydrochloride for pain.

The Environment Within: A Possible Link Identified Between Plasma Microbial Translocation & Autoantibody Development in 1st Degree Relatives of SLE Patients

Kurt Ullman  |  September 30, 2020

Plasma microbial translocation, the composition of the microbiome and environmental factors may influence the development of autoantibodies in patients with systemic lupus erythematosus (SLE), according to a study comparing SLE patients with their first-degree relatives and unrelated, healthy controls.

Arthroscopic Partial Meniscectomy Tied to Radiographic Knee OA

By Lisa Rapaport  |  September 29, 2020

(Reuters Health)—Patients with a degenerative meniscus tear who get arthroscopic partial meniscectomy have similar five-year outcomes and increased risk of radiographic knee osteoarthritis (OA) as without surgery, a small study suggests. Researchers in Finland randomly assigned 146 adults with degenerative meniscus tear confirmed by magnetic resonance imaging (MRI) to receive either arthroscopic partial meniscectomy (APM)…

State of the Art: Lupus—the Future Is Now

Keri Losavio  |  September 28, 2020

Sunday, Nov. 8, 2020, 10–11:00 a.m. EST: Several lupus trials this past year had positive results, bringing hope that new therapeutics may be available in the near future. This session will discuss how advances in our understanding of lupus pathogenesis have led to the development of different therapeutic strategies. Watch this page for our report…

PCSK9 Inhibitors May Lower Cholesterol in Patients with Statin-Associated Immune-Mediated Necrotizing Myopathy

Vanessa Caceres  |  September 23, 2020

A 2019 study demonstrated the benefit of a newer drug class, PCSK9 inhibitors, to help lower cholesterol in patients with statin-associated immune-mediated necrotizing myopathy…

Monthly Belimumab Infusions Preserve Kidney Function in Some Lupus Patients

Reuters Staff  |  September 21, 2020

(Reuters Health)—Intravenous belimumab combined with standard lupus therapy can help preserve kidney function in patients with active lupus nephritis and cut the odds of death or a renal-related event by half, a phase 3 multinational study has concluded.1 After two years of therapy, 43% of 224 volunteers getting the drug monthly showed a renal response…

  • « Previous Page
  • 1
  • …
  • 182
  • 183
  • 184
  • 185
  • 186
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences